Altimmune, Inc. (ALT)
NASDAQ
Market Cap
$610.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
431 of 963
Rank in Industry
255 of 552
Largest Insider Buys in Sector
ALT Stock Price History Chart
ALT Stock Performance
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Insider Activity of Altimmune, Inc.
Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $7.62M and sold $718,037 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, Altimmune, Inc.
| 2024-08-19 | Sale | director | 16,011 0.0206% | $6.90 | $110,547 | -7.69% | ||
| 2023-08-15 | director | 300 0.0006% | $2.88 | $863 | +149.13% | |||
| 2023-03-24 | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | |||
| 2023-03-23 | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | |||
| 2023-03-23 | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | |||
| 2022-12-22 | Sale | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | ||
| 2022-08-30 | Sale | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | ||
| 2022-08-12 | Sale | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.75% | ||
| 2022-08-12 | Sale | director | 2,714 0.0048% | $15.00 | $40,710 | -39.75% | ||
| 2022-07-01 | Sale | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | ||
| 2022-06-29 | Sale | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | ||
| 2022-06-27 | Sale | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | ||
| 2022-06-27 | Sale | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | |||
| 2022-06-15 | 1,000 0.002% | $8.00 | $8,000 | +36.66% | ||||
| 2022-05-24 | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | ||||
| 2022-02-28 | Sale | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | ||
| 2021-03-01 | Sale | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | ||
| 2020-12-10 | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% | |||
| 2020-12-01 | Sale | director | 1,227 0.0047% | $13.54 | $16,614 | -6.30% | ||
| 2020-11-30 | Sale | director | 2,500 0.0096% | $12.00 | $30,000 | +6.26% |
Insider Historical Profitability
<0.0001%
| Drutz David | director | 41958 0.059% | $8.59 | 6 | 1 | +23.34% |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 9.3166% | $8.59 | 1 | 3 | <0.0001% |
| EVNIN LUKE | 10 percent owner | 6347614 8.9246% | $8.59 | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 8.9246% | $8.59 | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 6.3269% | $8.59 | 4 | 0 | +64.5% |
| VELOCITY PHARMACEUTICAL HOLDINGS LLC | 10 percent owner | 1687250 2.3722% | $8.59 | 0 | 2 | |
| SCHAFFER DERACE L | director | 589453 0.8288% | $8.59 | 41 | 5 | <0.0001% |
| KINLEY MATTHEW P | 541000 0.7606% | $8.59 | 11 | 0 | ||
| WRIGHT DAVID P | President and CEO | 399500 0.5617% | $8.59 | 8 | 0 | +149.96% |
| PAPPAJOHN JOHN | director | 394044 0.554% | $8.59 | 15 | 3 | |
| Enright William | President and CEO | 365839 0.5144% | $8.59 | 1 | 0 | <0.0001% |
| HEALTHCARE VENTURES VII LP | 10 percent owner | 250000 0.3515% | $8.59 | 1 | 0 | |
| Garg Vipin K | President and CEO | 236797 0.3329% | $8.59 | 1 | 2 | +40.29% |
| RICHMAN ERIC I | director | 176822 0.2486% | $8.59 | 2 | 3 | |
| Riddle Valerie D | SVP, Medical Director | 44436 0.0625% | $8.59 | 0 | 3 | |
| Harris Matthew Scott | Chief Medical Officer | 33311 0.0468% | $8.59 | 1 | 2 | <0.0001% |
| SAYARE MITCHEL | director | 32650 0.0459% | $8.59 | 2 | 0 | <0.0001% |
| CHANG LINDA L | SVP, CFO & Secretary | 30000 0.0422% | $8.59 | 1 | 1 | |
| St Peter Steven | director | 25000 0.0351% | $8.59 | 1 | 0 | <0.0001% |
| Eisenstadt Richard I | Chief Financial Officer | 22010 0.0309% | $8.59 | 1 | 0 | <0.0001% |
| Runge Jeffrey W. | director | 20000 0.0281% | $8.59 | 2 | 0 | |
| FUERST THOMAS RICHARD | SVP, Chief Scientific Officer | 15000 0.0211% | $8.59 | 2 | 0 | |
| Karp Jordan P | SVP, General Counsel | 10000 0.0141% | $8.59 | 1 | 0 | |
| Schafer Klaus | director | 8900 0.0125% | $8.59 | 1 | 1 | +5.5% |
| Hodges Philip | director | 8731 0.0123% | $8.59 | 0 | 3 | |
| Pisano Wayne | director | 8498 0.0119% | $8.59 | 1 | 2 | <0.0001% |
| Roberts M Scot | Chief Scientific Officer | 8305 0.0117% | $8.59 | 1 | 3 | <0.0001% |
| GILL JOHN | director | 2771 0.0039% | $8.59 | 1 | 2 | <0.0001% |
| Price Kevin | President-Pharmathene UK, Ltd. | 2500 0.0035% | $8.59 | 1 | 0 | +153.68% |
| Jorkasky Diane | 0 0% | $8.59 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| State Street | $88.05M | 12.2 | 8.65M | +752.53% | +$77.72M | <0.01 | |
| BlackRock | $41.15M | 5.7 | 4.04M | -0.06% | -$25,256.58 | <0.01 | |
| The Vanguard Group | $31.85M | 4.41 | 3.13M | -12.41% | -$4.51M | <0.01 | |
| Tang Capital Management, LLC | $28M | 3.88 | 2.75M | 0% | +$0 | 0.11 | |
| Morgan Stanley | $22.52M | 3.12 | 2.21M | +112.5% | +$11.92M | <0.01 | |
| Ameriprise Financial | $17.4M | 2.41 | 1.71M | -59.14% | -$25.19M | 0.01 | |
| Millennium Management LLC | $16.19M | 2.24 | 1.59M | +813.14% | +$14.41M | 0.01 | |
| Geode Capital Management | $12.59M | 1.74 | 1.24M | +3.63% | +$440,547.42 | <0.01 | |
| Alger | $10.11M | 1.4 | 993,516 | +204.15% | +$6.79M | 0.05 | |
| Susquehanna International Group | $9.33M | 1.29 | 916,254 | +24.96% | +$1.86M | 0.01 | |
| Nuveen | $9.29M | 1.29 | 913,000 | -47.14% | -$8.29M | <0.01 | |
| Portolan Capital Management | $9.03M | 1.25 | 887,255 | New | +$9.03M | 0.7 | |
| Rafferty Asset Management Llc | $8.99M | 1.25 | 882,628 | New | +$8.99M | 0.03 | |
| Goldman Sachs | $8.77M | 1.22 | 861,415 | +64.31% | +$3.43M | <0.01 | |
| Readystate Asset Management Lp | $8.41M | 1.17 | 825,800 | New | +$8.41M | 0.47 | |
| Citigroup | $7.56M | 1.05 | 742,913 | +9,704.84% | +$7.49M | 0.01 | |
| Tupelo Capital Management LLC | $5.77M | 0.8 | 567,219 | +183.61% | +$3.74M | 0.14 | |
| Bank of America | $5.09M | 0.71 | 499,872 | +1,752.96% | +$4.81M | <0.0001 | |
| Northern Trust | $5.03M | 0.7 | 493,968 | +4.25% | +$205,015.05 | <0.01 | |
| UBS | $4.99M | 0.69 | 490,001 | +741.06% | +$4.4M | <0.01 | |
| Farallon Capital | $4.78M | 0.66 | 470,000 | +1,282.35% | +$4.44M | 0.03 | |
| Jacobs Levy Equity Management | $4.4M | 0.61 | 432,666 | +0.07% | +$3,308.50 | 0.02 | |
| BBR Partners | $3.65M | 0.51 | 358,513 | New | +$3.65M | 0.3 | |
| D. E. Shaw & Co. | $3.61M | 0.5 | 354,350 | +22.3% | +$657,872.32 | <0.01 | |
| Ensign Peak Advisors Inc | $3.33M | 0.46 | 326,777 | 0% | +$0 | 0.01 | |
| Group One Trading | $3.15M | 0.44 | 309,459 | -43.47% | -$2.42M | 0.04 | |
| Moody Aldrich Partners, LLC | $3.13M | 0.43 | 307,318 | New | +$3.13M | 0.53 | |
| Timelo Investment Management Inc. | $2.99M | 0.42 | 294,095 | -63.65% | -$5.24M | 5.48 | |
| Voya Investment Management LLC | $2.93M | 0.41 | 288,273 | +1,305.93% | +$2.73M | <0.01 | |
| Ardsley Advisory Partners | $2.8M | 0.39 | 275,000 | -19.36% | -$671,880.00 | 0.41 | |
| Beirne Wealth Consulting Services, LLC (BWC) | $2.78M | 0.39 | 272,800 | -10.2% | -$315,580.00 | 1.19 | |
| GHOST TREE CAPITAL LLC | $2.54M | 0.35 | 250,000 | New | +$2.54M | 0.03 | |
| Dimensional Fund Advisors | $2.39M | 0.33 | 234,730 | -10.24% | -$272,701.79 | <0.01 | |
| Woodline Partners LP | $2.18M | 0.3 | 214,245 | New | +$2.18M | 0.02 | |
| Schroder Investment Management Group | $1.94M | 0.27 | 190,824 | New | +$1.94M | <0.01 | |
| BNY Mellon | $1.93M | 0.27 | 189,654 | -1.01% | -$19,688.12 | <0.0001 | |
| Imc Chicago Llc | $1.69M | 0.23 | 165,607 | +25.71% | +$344,786.37 | 0.01 | |
| Wellington Management Company | $1.6M | 0.22 | 156,914 | New | +$1.6M | <0.0001 | |
| Lynwood Capital Management Inc. | $1.53M | 0.21 | 150,000 | New | +$1.53M | 14.1 | |
| Simplex Trading Llc | $1.49M | 0.21 | 146,259 | +124.56% | +$825,374.60 | 0.04 | |
| Charles Schwab | $1.45M | 0.2 | 142,705 | 0% | +$0 | <0.0001 | |
| Profund Advisors Llc | $1.37M | 0.19 | 134,842 | New | +$1.37M | 0.04 | |
| Raymond James Associates | $1.23M | 0.17 | 121,137 | New | +$1.23M | <0.01 | |
| Campbell Co Investment Adviser Llc | $1.12M | 0.16 | 110,213 | New | +$1.12M | 0.09 | |
| Pennant Capital Management Llc | $1.12M | 0.16 | 109,800 | 0% | +$0 | 0.18 | |
| Swiss National Bank | $1.08M | 0.15 | 106,000 | New | +$1.08M | <0.01 | |
| OMERS | $1.06M | 0.15 | 104,600 | New | +$1.06M | 0.01 | |
| Silvercrest Asset Management Group Inc | $1.05M | 0.15 | 103,500 | 0% | +$0 | 0.01 | |
| Jane Street Capital | $1.03M | 0.14 | 101,577 | -82.5% | -$4.87M | <0.01 | |
| Schonfeld Group | $1.03M | 0.14 | 101,426 | -24.87% | -$341,783.09 | 0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.